Arpit Rao
Hematology & Oncology · Minneapolis, MNNPI 1982991170
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Pfizer at 39.4% of the total. Reporting peaked in 2023 at $18,165 and has fallen 99.6% since, to $77 in 2025. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $709.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$18K
- E.r. Squibb & Sons, L.L.C.$6K
- Eli Lilly$5K
- Dendreon Pharmaceuticals LLC$5K
- Janssen Global Services, LLC$3K
- Sanofi$2K
- plus $7K from 11 others
Across 422 payments — averaging $3679.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$562K
- Clovis Oncology, Inc.$356K
- Eli Lilly$295K
- Seagen Inc.$282K
- E.r. Squibb & Sons, L.L.C.$58K
What the payments were for
- Consulting fees$23,40651%
- Speaking & faculty fees$14,28531%
- Travel & lodging$6,31814%
- Food & beverage$2,1085%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $18,168 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,075 |
| Eli Lilly | 19 | $5,020 |
| Dendreon Pharmaceuticals LLC | 3 | $4,507 |
| Janssen Global Services, LLC | 1 | $2,700 |
| Sanofi | 3 | $2,353 |
| Bayer | 1 | $2,284 |
| Eisai Inc. | 1 | $2,280 |
| AVEO Pharmaceuticals, Inc. | 1 | $2,100 |
| Inari Medical, Inc. | 1 | $140 |
| Johnson & Johnson | 4 | $138 |
| AstraZeneca | 2 | $118 |
| EMD Serono, Inc. | 1 | $94 |
| Intuitive Surgical | 1 | $77 |
| Amgen | 2 | $44 |
| Merck | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,118 in reported general payments places this provider in the 90th percentile of 193 hematology & oncology providers in Minnesota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Minneapolis
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Vicki MorrisonMinneapolis$354K
- Aimee MerinoMinneapolis$161K
- Daniel WeisdorfMinneapolis$64K
- Gautam JhaMinneapolis$55K
- Amit KulkarniMinneapolis$40K
- Gregory VercellottiMinneapolis$34K
- Veronika BachanovaMinneapolis$33K
- Marshall MazepaMinneapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.